Silo Pharma price to sales ratio SILO

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 34.7×
5-year median: 77.5×
Against its 5-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
5-year range: 26.7× to 198×
Peer median: 0.4×

Silo Pharma's price to sales ratio is 34.7× as of Oct 23, 2026.

That is below its 5-year median of 77.5×, lower than on 98% of days in the last 5 years.

Over that time it ranged from 26.7× in May 2025 to 198× in Aug 2021.

The median for 5 healthcare stocks of a similar size is 0.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	34.7×	34.7×	101×
2025	67.4×	26.7×	123×
2024	58.5×	37.4×	95.6×
2023	n/m a value too high to mean anything
2022	97.6×	90.0×	124×
2021	91.7×	86.5×	198×

Against its peers

Companies in Healthcare nearest Silo Pharma's size, closest first, today.

Company	Price to sales ratio
SILOSilo Pharma	34.7×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
Peer median	0.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Silo Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.